首页> 外文期刊>Research journal of pharmacy and technology >Registration and Regulatory Requirements of Generic Drugs Marketing Authorization in 'BRICS' Countries
【24h】

Registration and Regulatory Requirements of Generic Drugs Marketing Authorization in 'BRICS' Countries

机译:“金砖金”国家普通药物营销授权的注册和监管要求

获取原文
获取原文并翻译 | 示例
       

摘要

The comparative study of generic drug registration in BRICS, was to find out the differences among the guidelines. "BRICS" mainly refers to Brazil, Russia, India, china and South Africa. The regulatory requirements of each country is different from each other, "BRICS" has the fastest growing and largest emerging markets which shows the positive growth in the pharmaceutical companies. The medical regulatory system in the BRICS countries is increasing in the medical profession to safeguard and promote the medicine. The BRICS countries together is consider as important emerging economics, which has 40% of world population. To develop the universal health coverage, The BRICS countries of national institution agreed to join hands with (WHO), world health organization.
机译:金砖石中仿制药物登记的比较研究,是为了了解指导方针之间的差异。 “Brics”主要是指巴西,俄罗斯,印度,中国和南非。 每个国家的监管要求与彼此不同,“金砖石”具有最快的增长和最大的新兴市场,显示了制药公司的积极增长。 金砖国家的医疗监管制度在医学职业中越来越多,保障和促进药物。 金砖国家共同认为是重要的新兴经济学,占世界人口的40%。 为了制定普遍的健康覆盖范围,国内机构的金砖国家同意与世界卫生组织的(世卫组织)携手共进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号